Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LGVN Longeveron Inc

Pre-Market Trading 11-21 09:19:19 EST

1.85

+0.00

0.00%

盘前1.84

-0.01-0.54%

09:09 EST

High1.90	Low1.78	Vol299.32K
Open1.84	D1 Closing1.85	Amplitude6.41%
Mkt Cap26.57M	Tradable Cap20.69M	Total Shares14.36M
T/O556.54K	T/O Rate2.68%	Tradable Shares11.19M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":1.85,"timestamp":1732136400000,"preClose":1.85,"halted":0,"volume":299324,"hourTrading":{"tag":"盘前","latestPrice":1.84,"preClose":1.85,"latestTime":"09:09 EST","volume":1210,"amount":2224.394425,"timestamp":1732198168460},"delay":0,"floatShares":11186188,"shares":14359478,"eps":-4.361456,"marketStatus":"Pre-Market Trading","change":0,"latestTime":"11-21 09:19:19 EST","open":1.84,"high":1.9,"low":1.7815,"amount":556543.3800132,"amplitude":0.064054,"askPrice":1.88,"askSize":900,"bidPrice":1.82,"bidSize":1098,"shortable":3,"etf":0,"ttmEps":-4.361456,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732199400000},"marketStatusCode":1,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":1.85,"preHourTrading":{"tag":"盘前","latestPrice":1.84,"preClose":1.85,"latestTime":"09:09 EST","volume":1210,"amount":2224.394425,"timestamp":1732198168460},"postHourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.85,"latestTime":"18:58 EST","volume":139661,"amount":259759.0894,"timestamp":1732147098553},"volumeRatio":0.5093205158824442},"requestUrl":"/m/hq/s/LGVN/tweets","defaultTab":"tweets","newsList":[{"id":"2483225793","title":"We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483225793","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483225793?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:43","pubTimestamp":1731670998,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So should Longeveron  shareholders be worried about its cash burn?For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.How Is Longeveron's Cash Burn Changing Over Time?Longeveron's cash burn of US$16m is about 52% of its US$30m market capitalisation. From this perspective, it seems that the company spent a huge amount relative to its market value, and we'd be very wary of a painful ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-keeping-eye-longeverons-nasdaq-114318260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","LU2210149790.SGD","TQQQ","BK4139","MNQmain","IE00BKPKM429.USD","PSQ","LU2210150020.SGD","SQQQ","BK4112","QID","BK4585","QLD","LU2095319765.USD","NDAQ","BK4588","IE00B3QW5Z07.USD","NQmain","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LGVN"],"gpt_icon":1},{"id":"2483483919","title":"LGVN Highlights Potential Groundbreaking Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2483483919","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483483919?lang=en_us&edition=fundamental","pubTime":"2024-11-13 17:00","pubTimestamp":1731488400,"startTime":"0","endTime":"0","summary":"Longeveron  is a company that should be getting more attention from investors. LGVN has made substantial progress with its signature treatment, Lomecel-B, in treating both HLHS and Alzheimer's Disease and we suggest investors take a look at this stock before more good news comes out—such as what happened recently. The company announced follow up results of its Phase 1 trial of Lomecel-B for the treatment of HLHS . The results were very impressive and have the potential to give hope to parents of children with this devastating disease. Those results follow the quarterly results that LGVN just released.To assess long-term survival benefits, all ELPIS I patients  were followed for five years post-Glenn surgery and treatment with Lomecel-Bto evaluate overall survival and transplant-free survival. Outcomes were compared with long-term historical data from patients in the Single Ventricle Reconstruction  Trial receiving the same shun","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lgvn-highlights-potential-groundbreaking-treatments-090000843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","MACE","BK4139","BK4157","LGVN"],"gpt_icon":0},{"id":"2483448063","title":"Longeveron reports Q3 EPS (34c), consensus (44c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483448063","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483448063?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:50","pubTimestamp":1731448247,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $210, consensus $400k .”In the third quarter, we continued to advance the development of our investigational cellular therapy ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-reports-q3-eps-34c-consensus-44c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-reports-q3-eps-34c-consensus-44c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN"],"gpt_icon":0},{"id":"2483407050","title":"Longeveron Q3 2024 GAAP EPS $(0.34) Beats $(0.44) Estimate, Sales $773.000K Beat $397.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483407050","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483407050?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:34","pubTimestamp":1731447285,"startTime":"0","endTime":"0","summary":"Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.44) by 22.73 percent. This is a 87.81 percent increase over losses of $(2.79) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41920789/longeveron-q3-2024-gaap-eps-0-34-beats-0-44-estimate-sales-773-000k-beat-397-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Longeveron Q3 2024 GAAP EPS $(0.34) Beats $(0.44) Estimate, Sales $773.000K Beat $397.000K Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"gpt_icon":1},{"id":"2483052124","title":"Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483052124","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483052124?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"Wa'el Hashad   Wa'el Hashad, CEO, Longeveron  Phase 2b clinical trial (ELPIS II) evaluating Lomecel-Bin rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979713/0/en/Longeveron-Announces-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSC","BK4139","BK4150","BK4157","BK4575","BK4183","MACE","LGVN","AAIC","BK4110"],"gpt_icon":1},{"id":"2482373863","title":"Longeveron Names Devin Blass Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2482373863","media":"MT Newswires Live","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482373863?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:41","pubTimestamp":1731336114,"startTime":"0","endTime":"0","summary":"Longeveron  said Monday that it has named Devin Blass chief technology officer, effective Dec. 2.Blass, who has more than 15 years of experience, previously served as senior vice president of comprehensive cell solutions at the New York Blood Center Enterprises.Price: 2.20, Change: -0.01, Percent Change: -0.23","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2482528787","title":"Longeveron appoints Blass as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2482528787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482528787?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:10","pubTimestamp":1731334245,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that it has appointed Devin Blass as Chief Technology Officer, CTO, and Senior Vice President of Chemistry, Manufacturi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-appoints-blass-as-chief-technology-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-appoints-blass-as-chief-technology-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LGVN"],"gpt_icon":0},{"id":"2482078223","title":"Longeveron® Appoints Devin Blass as Chief Technology Officer and Svp of Chemistry, Manufacturing and Controls (Cmc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482078223","media":"THOMSON REUTERS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482078223?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:05","pubTimestamp":1731333900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA3KSD34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2482782254","title":"Press Release: Longeveron(R) Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482782254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482782254?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:05","pubTimestamp":1731333900,"startTime":"0","endTime":"0","summary":"Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls . MIAMI, Nov. 11, 2024  -- Longeveron Inc. , a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer  and Senior Vice President of Chemistry, Manufacturing, and Controls , effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies.\"I am thrilled to join Longeveron as the CTO and SVP of CMC,\" said Mr. Blass. \"Longeveron's commitment to advancing regenerative medicine aligns with my passion for developing innovative therapies. I look forward to contributing to the Company's mission and driving forward our technological and manufacturing strategies to bring transformative treatments to patients.\". Longeveron is a clinical stage biotechnology company developing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4006","IE00B1BXHZ80.USD","CTO","BK4585","03160","LU0882574139.USD","LU0971096721.USD","IE00BZ1G4Q59.USD","BK4150","LU0170899867.USD","CDMO","CMC","LGVN","LU0149725797.USD","BK4160","IE00BHPRN162.USD","TM","R","WRD","BK4588","BK4555","BK4022","IE00BKVL7J92.USD","LU0267386448.USD","BK4232","MSC","BK4575","BK4139","LU1363072403.SGD"],"gpt_icon":0},{"id":"2481955421","title":"Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481955421","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481955421?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:05","pubTimestamp":1730754300,"startTime":"0","endTime":"0","summary":"MIAMI, Nov. 04, 2024  -- Longeveron Inc. , a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j.mzAIDdWCTvAqa_P7faeg--~B/aD0yMDY7dz0xMTEzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8bd00e830e0e46e66bdf61650be465c7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j.mzAIDdWCTvAqa_P7faeg--~B/aD0yMDY7dz0xMTEzO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8bd00e830e0e46e66bdf61650be465c7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/longeveron-report-third-quarter-2024-210500278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4150","BK4575","HST","BK4139","MSC","BK4218","LGVN","BK4588","BK4181","BK4585"],"gpt_icon":1},{"id":"2480309516","title":"Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2480309516","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480309516?lang=en_us&edition=fundamental","pubTime":"2024-11-04 19:49","pubTimestamp":1730720940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LGVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 06:49 ET (11:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"gpt_icon":0},{"id":"2479851912","title":"Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (Ctad24)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479851912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479851912?lang=en_us&edition=fundamental","pubTime":"2024-10-29 22:00","pubTimestamp":1730210400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA9ZRR5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2479825286","title":"Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479825286","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479825286?lang=en_us&edition=fundamental","pubTime":"2024-10-29 22:00","pubTimestamp":1730210400,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron. Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-Bfor mild Alzheimer’s disease . Lomecel-Bcapacity to inhibit MMP14 correlates with improved clinical and biomarker outcomes in mild AD. Immunomodulatory and pro-vascular effects of Lomecel-Bin mild AD potentially driven by ability to exert MMP14 inhibition which may protect TIE2 receptor integrity in human AD patients. The researchers measured MMP14 inhibitory  activity, levels of TIMP2 , and VEGF-A  in the lots of Lomecel-B used in the CLEAR MIND trial. Supernatant from Lomecel-B CLEAR MIND lots contained MMP14i activity, high levels of TIMP2 and VEGF-A protein. Patients receiving Lomecel-B lots with higher levels of MMP14i activity demonstrated enhanced responses vs. placebo on the composite Alzheimer’s disease score  than those who received","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TnMuNoVzrkhCoTbAaFsaGw--~B/aD0xMTk7dz0xMDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TnMuNoVzrkhCoTbAaFsaGw--~B/aD0xMTk7dz0xMDk7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f7a2ba21ee9ad9d0faddab0a429da6e8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/longeveron-presents-lomecel-b-data-140000230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4575","BK4150","LGVN","MSC"],"gpt_icon":1},{"id":"2478438172","title":"LGVN Announces Treatment Garners Excellent Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2478438172","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478438172?lang=en_us&edition=fundamental","pubTime":"2024-10-28 19:09","pubTimestamp":1730113740,"startTime":"0","endTime":"0","summary":"Longeveron  is a company that should be getting more attention from investors. LGVN has made substantial progress with its signature treatment, Lomecel-B, in treating both HLHS and Alzheimer's Disease and we suggest investors take a look at this stock before more good news comes out—such as what happened recently. The company announced follow up results of its Phase 1 trial of Lomecel-B for the treatment of HLHS . The results were very impressive and have the potential to give hope to parents of children with this devastating disease.In order to understand how important these results are, investors need to understand how devastating HLHS can be. HLHS is a rare pediatric congenital heart birth defect in which the left ventricle  is either severely underdeveloped or missing. It is a devastating diagnosis for families with only 20-60% of babies with HLHS surviving their first year of life according to data compiled by the Cleveland Clinic.According to the company, these findings support t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lgvn-announces-treatment-garners-excellent-110900623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4157","MACE","LGVN","BK4183","BK4139"],"gpt_icon":0},{"id":"2478139194","title":"Longeveron presents Lomecel-B long-term transplant-free survival data in HLHS","url":"https://stock-news.laohu8.com/highlight/detail?id=2478139194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478139194?lang=en_us&edition=fundamental","pubTime":"2024-10-28 05:50","pubTimestamp":1730065804,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced that its positive long-term transplant-free survival data from a multi-year follow-on study to the ELPIS I Phase 1 clin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeveron-presents-lomecel-b-long-term-transplant-free-survival-data-in-hlhs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeveron-presents-lomecel-b-long-term-transplant-free-survival-data-in-hlhs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2478219346","title":"BRIEF-Longeveron Says Elpis I Met Its Primary Endpoint Of Safety Through 1-Year Post-Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2478219346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478219346?lang=en_us&edition=fundamental","pubTime":"2024-10-28 03:12","pubTimestamp":1730056322,"startTime":"0","endTime":"0","summary":"Oct 27 (Reuters) - Longeveron Inc   :   * LONGEVERON INC - ELPIS I MET ITS PRIMARY ENDPOINT OF SAFETY THROUGH 1-YEAR POST-TREATMENT   * LONGEVERON INC - ELPIS II PHASE 2B CLINICAL TRIAL IS CURRENTLY ONGOINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN","POST","BK4212"],"gpt_icon":0},{"id":"2478464193","title":"Longeveron Inc - Elpis Ii Phase 2B Clinical Trial Is Currently Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2478464193","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478464193?lang=en_us&edition=fundamental","pubTime":"2024-10-28 03:10","pubTimestamp":1730056223,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241027:nFWN3M12EO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2478193461","title":"Longeveron Inc - Elpis I Met Its Primary Endpoint of Safety Through 1-Year Post-Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2478193461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478193461?lang=en_us&edition=fundamental","pubTime":"2024-10-28 03:10","pubTimestamp":1730056223,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241027:nFWN3M12EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LGVN","BK4139"],"gpt_icon":0},{"id":"2478193224","title":"Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2478193224","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478193224?lang=en_us&edition=fundamental","pubTime":"2024-10-28 03:10","pubTimestamp":1730056200,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/27/2969739/0/en/Longeveron-Presents-Lomecel-B-Long-term-Transplant-free-Survival-Data-in-Hypoplastic-Left-Heart-Syndrome-HLHS-at-the-Congenital-Heart-Surgeons-Society-CHSS-51st-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","BK4575","MACE","BK4157","BK4183","BK4139","LGVN","MSC"],"gpt_icon":1},{"id":"2475136159","title":"BRIEF-Longeveron® Lomecel-B™ Data In Alzheimer’S Disease Selected For Late Breaking Poster Presentation At The Clinical Trials On Alzheimer’S Disease Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2475136159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475136159?lang=en_us&edition=fundamental","pubTime":"2024-10-14 21:07","pubTimestamp":1728911248,"startTime":"0","endTime":"0","summary":"Oct 14 (Reuters) - Longeveron Inc   :   * LONGEVERON® LOMECEL-B™ DATA IN ALZHEIMER’S DISEASE SELECTED FOR LATE BREAKING POSTER PRESENTATION AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD24)Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.1274},{"period":"1month","weight":-0.1148},{"period":"3month","weight":-0.2966},{"period":"6month","weight":0.6818},{"period":"1year","weight":-0.9021},{"period":"ytd","weight":-0.864}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.243376},{"month":2,"riseRate":0,"avgChangeRate":-0.072728},{"month":3,"riseRate":0.25,"avgChangeRate":0.054898},{"month":4,"riseRate":0.25,"avgChangeRate":-0.183032},{"month":5,"riseRate":0.5,"avgChangeRate":-0.110991},{"month":6,"riseRate":0.75,"avgChangeRate":0.140794},{"month":7,"riseRate":0.5,"avgChangeRate":0.170001},{"month":8,"riseRate":0,"avgChangeRate":-0.289561},{"month":9,"riseRate":0.25,"avgChangeRate":-0.107166},{"month":10,"riseRate":0.25,"avgChangeRate":-0.031272},{"month":11,"riseRate":0.5,"avgChangeRate":1.640879},{"month":12,"riseRate":0,"avgChangeRate":-0.338864}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Longeveron Inc(LGVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction